Immunic, Inc. Announces Closing of $45.0 Million Public Offering

Immunic, Inc. Announces Closing of…

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

Immunic, Inc. Announces FDA Clearance…

Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838

Immunic and 4SC AG Sign…

Immunic, Inc. Announces Positive Top-Line Data From Investigator- Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

Immunic, Inc. Announces Positive Top-Line…

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

Immunic, Inc. Announces That Oral…

Immunic, Inc. Added to NASDAQ Biotechnology Index

Immunic, Inc. Added to NASDAQ…

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed

Immunic, Inc. Announces 200 Patients…

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy

EIB Provides Immunic With up…

Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function

Immunic, Inc. Announces Dosing of…

Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Immunic, Inc. Announces Closing of…